Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$161.01 - $317.85 $26.5 Million - $52.3 Million
-164,621 Reduced 93.4%
11,631 $3.68 Million
Q3 2023

Nov 14, 2023

SELL
$164.66 - $218.08 $94,514 - $125,177
-574 Reduced 0.32%
176,252 $29.8 Million
Q2 2023

Aug 14, 2023

BUY
$176.32 - $240.22 $27.1 Million - $36.9 Million
153,451 Added 656.47%
176,826 $38.3 Million
Q1 2023

May 15, 2023

BUY
$161.33 - $204.36 $915,547 - $1.16 Million
5,675 Added 32.06%
23,375 $4.25 Million
Q3 2022

Nov 14, 2022

SELL
$123.79 - $277.42 $198,064 - $443,872
-1,600 Reduced 8.29%
17,700 $3.98 Million
Q2 2022

Aug 15, 2022

BUY
$93.97 - $143.33 $140,955 - $214,995
1,500 Added 8.43%
19,300 $2.44 Million
Q1 2022

May 16, 2022

SELL
$98.9 - $132.37 $138,460 - $185,318
-1,400 Reduced 7.29%
17,800 $2.26 Million
Q4 2021

Feb 14, 2022

BUY
$110.64 - $159.4 $2.12 Million - $3.06 Million
19,200 New
19,200 $2.52 Million

Others Institutions Holding KRTX

About Karuna Therapeutics, Inc.


  • Ticker KRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 33,965,000
  • Description
  • Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients wi...
More about KRTX
Track This Portfolio

Track Patient Capital Management, LLC Portfolio

Follow Patient Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Patient Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Patient Capital Management, LLC with notifications on news.